Related Experiment Video
Updated: Aug 2, 2025
06:17
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
12.0K
Peroxynitric acid inhibits amyloid β aggregation.
Haruka Kawabe1, Satoshi Ikawa2, Katsuhisa Kitano3
1Department of Chemistry and Biology, Graduate School of Science and Engineering, Ehime University, 2-5 Bunkyo, Matsuyama, Ehime, 790-8577, Japan.
Biochemical and Biophysical Research Communications
|April 14, 2023
Summary
Peroxynitric acid (PNA) shows potential for protein modification. This study demonstrates PNA inhibits amyloid-beta aggregation, offering a novel strategy against Alzheimer
Area of Science:
- Biochemistry
- Neuroscience
- Reactive Oxygen Species Research
Background:
- Peroxynitric acid (PNA) is a reactive oxygen nitrogen species with potent bactericidal properties.
- PNA's reactivity with amino acid residues suggests potential for protein modification applications.
- Amyloid beta-42 (Aβ42) aggregation is implicated in the pathogenesis of Alzheimer's disease (AD).
Purpose of the Study:
- To investigate the potential of PNA for protein modification.
- To evaluate PNA's efficacy in inhibiting the aggregation and cytotoxicity of amyloid beta-42 (Aβ42).
Main Methods:
- Treatment of Aβ42 with peroxynitric acid (PNA).
- Assessment of Aβ42 aggregation using biophysical techniques.
- Evaluation of Aβ42-induced cytotoxicity in cellular models.
Main Results:
- PNA effectively inhibited the aggregation of Aβ42.
- PNA reduced the cytotoxicity associated with Aβ42.
- PNA demonstrated inhibitory effects on the aggregation of other amyloidogenic proteins, including amylin and insulin.
Conclusions:
- Peroxynitric acid (PNA) is a novel agent capable of inhibiting amyloidogenic protein aggregation.
- PNA presents a new therapeutic strategy for preventing diseases associated with amyloid formation, such as Alzheimer's disease.
Related Concept Videos
03:03Amyloid Fibrils
9.7K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.7K
01:22Alzheimer's Disease: Treatment
231
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
231
01:29Drugs Affecting Neurotransmitter Synthesis
1.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.5K